This philosophy has led us to specialize in experimental oncology and to develop a pipeline focused on innovative small molecules, including Fraisinib, a first-in-class inhibitor of the Glycyl-tRNA synthetase 1 (GARS1) protein.

VISION

SHAPING THE FUTURE OF ONCOLOGY

We believe in a future where cancer therapies are more targeted, intelligent, and tolerable. Our goal is not only to treat, but also to preserve the patient’s quality of life.

This is why we invest in ethical and selective research, at the frontier between nature and technology, to turn scientific insights into real-world solutions. Driven by a pioneering vision, we work every day to shape the future of medicine with passion, precision, and responsibility.

INNOVATION

Innovating oncology with intelligence, safety, and courage, turning every discovery into a concrete hope.

OUR TEAM

SCIENTIFIC ADVISORY BOARD -INVENTORS

OPINION LEADER